Tokyo, Japan

Kazuhiro Momose


Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kazuhiro Momose: Innovator in NAD(P)H Oxidase Inhibitors

Introduction

Kazuhiro Momose is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target NAD(P)H oxidase inhibitors. His work has implications for the treatment of various metabolic disorders.

Latest Patents

Kazuhiro Momose holds a patent for a quinolone derivative. This compound exhibits excellent NAD(P)H oxidase inhibitory activity, which is crucial for preventing and treating conditions such as diabetes, impaired glucose tolerance, hyperlipidemia, and fatty liver. The innovative nature of this compound lies in its ability to inhibit reactive oxygen species production, making it a valuable agent in the medical field.

Career Highlights

Kazuhiro Momose is associated with Astellas Pharma GmbH, a leading pharmaceutical company. His research and development efforts have led to advancements in therapeutic agents that address critical health issues. His dedication to innovation in the pharmaceutical industry is evident through his focused research on NAD(P)H oxidase inhibitors.

Collaborations

Kazuhiro has collaborated with notable colleagues, including Kenichi Onda and Kenichiro Imamura. These partnerships have fostered a collaborative environment that enhances the research and development process, leading to groundbreaking discoveries in the field.

Conclusion

Kazuhiro Momose's contributions to the field of medicinal chemistry, particularly through his patent on a quinolone derivative, highlight his role as an innovator in the pharmaceutical industry. His work continues to pave the way for advancements in the treatment of metabolic disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…